A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
Quest Diagnostics and Oxford Immunotec Global announced this week that Quest has completed its previously announced acquisition of Oxford Immunotec's US laboratory services business.
The company posted $29.3 million in revenues for the quarter, including $25 million from its tuberculosis business, which grew 17 percent year over year.
The agency cleared two Roche tests that run on its Cobas systems. One does Chlamydia trachomatis and Neisseria gonorrhoeae testing and the other does hematology testing.